



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 49/00</b>		(11) International Publication Number: <b>WO 99/20312</b>														
<b>A1</b>		(43) International Publication Date: 29 April 1999 (29.04.99)														
<p>(21) International Application Number: PCT/GB98/03155</p> <p>(22) International Filing Date: 21 October 1998 (21.10.98)</p> <p>(30) Priority Data:</p> <table border="0"> <tr> <td>9722224.4</td> <td>21 October 1997 (21.10.97)</td> <td>GB</td> </tr> <tr> <td>9809099.6</td> <td>28 April 1998 (28.04.98)</td> <td>GB</td> </tr> </table> <p>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications</p> <table border="0"> <tr> <td>US</td> <td>60/071,710 (CIP)</td> </tr> <tr> <td>Filed on</td> <td>16 January 1998 (16.01.98)</td> </tr> <tr> <td>US</td> <td>60/084,879 (CIP)</td> </tr> <tr> <td>Filed on</td> <td>8 May 1998 (08.05.98)</td> </tr> </table> <p>(71) Applicant (for all designated States except US): NYCOMED IMAGING AS [NO/NO]; Nycoveien 2, P.O. Box 4220 Torshov, N-0401 Oslo (NO).</p> <p>(71) Applicant (for GB only): MARSDEN, John, Christopher [GB/GB]; Frank B. Dehn &amp; Co., 179 Queen Victoria Street, London EC4V 4EL (GB).</p>		9722224.4	21 October 1997 (21.10.97)	GB	9809099.6	28 April 1998 (28.04.98)	GB	US	60/071,710 (CIP)	Filed on	16 January 1998 (16.01.98)	US	60/084,879 (CIP)	Filed on	8 May 1998 (08.05.98)	<p>(72) Inventors; and (75) Inventors/Applicants (for US only): ERIKSEN, Morten [NO/NO]; Nycomed Imaging as, Nycoveien 2, P.O. Box 4220 Torshov, N-0401 Oslo (NO). ØSTENSEN, Jonny [NO/NO]; Nycomed Imaging as, Nycoveien 2, P.O. Box 4220 Torshov, N-0401 Oslo (NO). FRIGSTAD, Sigmund [NO/NO]; Frode Rinnans vei 68, N-7035 Trondheim (NO). RONGVED, Pål [NO/NO]; Nycomed Imaging as, Nycoveien 2, P.O. Box 4220 Torshov, N-0401 Oslo (NO).</p> <p>(74) Agents: MARSDEN, John, Christopher et al.; Frank B. Dehn &amp; Co., 179 Queen Victoria Street, London EC4V 4EL (GB).</p> <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>
9722224.4	21 October 1997 (21.10.97)	GB														
9809099.6	28 April 1998 (28.04.98)	GB														
US	60/071,710 (CIP)															
Filed on	16 January 1998 (16.01.98)															
US	60/084,879 (CIP)															
Filed on	8 May 1998 (08.05.98)															
<p>(54) Title: ULTRASOUND IMAGING WITH CONTRAST AGENT TARGETED TO MICROVASCULATURE AND A VASODILATOR DRUG</p> <p>(57) Abstract</p> <p>A combined preparation comprising: i) an ultrasound contrast agent capable of accumulation in tissue microvasculature; and ii) a pharmacologically effective amount of a vasodilator drug may be used in perfusion imaging, especially of the myocardium. The contrast agent accumulates in tissue in concentrations related to the regional rate of tissue perfusion, and the vasodilator drug enhances distinction between normally perfused and underperfused tissue.</p>																

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

ULTRASOUND IMAGING WITH CONTRAST AGENT TARGETED TO MICROVASCULATURE AND A  
VASODILATOR DRUG

5           This invention relates to ultrasound imaging, more particularly to use of ultrasound imaging in visualising tissue perfusion, i.e. blood flow per unit of tissue mass, in particular cardiac perfusion.

10           It is well known that contrast agents comprising dispersions of gas microbubbles are particularly efficient backscatterers of ultrasound by virtue of the low density and ease of compressibility of the microbubbles. Such microbubble dispersions, if appropriately stabilised, may permit highly effective  
15           ultrasound visualisation of, for example, the vascular system and tissue microvasculature, often at advantageously low doses.

          Measurements of tissue perfusion are of importance in, for example, tumour detection, tumour tissue  
20           typically having different vascularity from healthy tissue, and studies of the myocardium, e.g. to evaluate the blood supply thereto. Whilst contrast agent detection using current ultrasound imaging techniques may provide information as to whether particular organs  
25           or regions thereof are perfused or not, it does not readily permit quantification of levels of perfusion. Such information, which is useful in assessing whether a patient is at risk owing to low perfusion and so may benefit from preventative methods and/or treatment, must  
30           currently be obtained using radioisotopic imaging techniques such as scintigraphy, positron emission tomography or single photon emission computed tomography. These techniques all involve injection of radioactive substances, with potential safety risks for  
35           both the patient and medical staff, and use of expensive imaging equipment; this inevitably prohibits their widespread use.

- 2 -

It is known from radionuclide cardiac imaging that patients may be subjected to physical or pharmacological stress in order to enhance the distinction, and thus the difference in imaging intensities, between normally perfused myocardium and any myocardial regions supplied by stenotic arteries. Such stress induces vasodilatation and increased blood flow in healthy myocardial tissue, whereas blood flow in underperfused tissue supplied by a stenotic artery is substantially unchanged since the capacity for arteriolar vasodilatation is already exhausted by inherent autoregulation seeking to increase the restricted blood flow.

The application of stress as physical exercise or pharmacologically by administration of adrenergic agonists may cause discomfort such as chest pains in patient groups potentially suffering from heart disease, and it is therefore preferable to enhance the perfusion of healthy tissue by administration of a vasodilating drug.

The present invention is based on the finding that ultrasound contrast agents capable of accumulation in tissue microvasculature may be used in perfusion imaging, especially of the myocardium, when coadministered with a pharmacologically effective amount of a vasodilating drug. Because such contrast agents will accumulate in tissue in concentrations related to the regional rate of tissue perfusion, ultrasound imaging modalities such as conventional or harmonic B-mode imaging where the display is derived from return signal intensities will provide images which may be interpreted as perfusion maps in which the displayed signal intensity is a function of local perfusion. This is in contrast to images obtained using free-flowing contrast agents, where the regional concentration of contrast agent and corresponding return signal intensity depend on the actual blood content

- 3 -

rather than the rate of perfusion of local tissue.

A disadvantage of existing radionuclide cardiac imaging techniques is that the uptake of radionuclide tracers such as thallium 201 and technetium sestamibi is limited by low contact time between tracer and tissue and so may require maintenance of vasodilatation for the whole period of blood pool distribution for the tracer (e.g. 4-6 minutes for thallium scintigraphy) to ensure optimum effect. Accumulative ultrasound contrast agents used in accordance with the present invention, on the other hand, do not suffer such diffusion or transport limitations and, especially where accumulation occurs through a process of physical entrapment, may undergo highly efficient retention in tissue microvasculature. The period of vasodilatation needed to achieve cardiac or other perfusion imaging in accordance with the invention may therefore be short, for example less than one minute; this will reduce the duration of any possible discomfort caused to patients by administration of vasodilator drugs.

In accordance with one embodiment of the invention there is provided a combined preparation for use as a contrast agent in ultrasound perfusion imaging, especially cardiac perfusion imaging, said preparation comprising:

- i) an ultrasound contrast agent capable of accumulation in tissue microvasculature, e.g. of the myocardium; and
- ii) a pharmacologically effective amount of a vasodilator drug.

According to a further embodiment of the invention there is provided a method of generating enhanced perfusion images, especially cardiac perfusion images, of a human or non-human animal subject which comprises the steps of:

- i) injecting an ultrasound contrast agent capable of accumulation in tissue microvasculature, e.g. of the

- 4 -

myocardium, into the vascular system of said subject;

ii) coadministering a pharmacologically effect amount of a vasodilator drug; and

iii) generating an ultrasound image representing perfusion of a target organ or tissue, especially the myocardium.

Representative vasodilator drugs useful in accordance with the invention include endogenous/metabolic vasodilators such as lactic acid, adenosine triphosphate, adenosine diphosphate, adenosine monophosphate, adenosine, nitric oxide and agents causing hypercapnia, hypoxia/hypoxemia or hyperemia; phosphodiesterase inhibitors such as dipyridamole and sildenafil; sympathetic activity inhibitors such as clonidine and methyl dopa; smooth muscle relaxants such as papaverine, hydralazine, dihydralazine and nitroprusside; beta receptor agonists such as dopamine, dobutamine, arbutamine, albuterol, salmeterol and isoproterenol; alpha receptor antagonists such as doxazosin, terazosin and prazosin; organic nitrates, such as glyceryl trinitrate, isosorbide dinitrate and isosorbide mononitrate; angiotensin converting enzyme (ACE) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, quinapril and ramipril; angiotensin II antagonists (or AT1 receptor antagonists) such as valsartane, losartan and candesartan; calcium channel blockers such as amlodipine, nicardipine, nimodipine, felodipine, isradipine, diltiazem, verapamil and nifedipine; prostaglandins such as alprostadil; and endothelium-dependent vasodilators.

In view of the fact that the required vasodilatation may need only to be short lasting, adenosine is a particularly useful vasodilating drug, being both an endogenous substance and having a very short-lasting action as evidenced by a blood pool half-life of only a few seconds. Vasodilatation will

- 5 -

accordingly be most intense in the heart, since the drug will tend to reach more distal tissues in less than pharmacologically active concentrations, and may result in coronary blood flow in healthy myocardial tissue increasing by more than 400%. It will be appreciated that because of this short half-life, repeated injection or infusion of adenosine may be necessary during cardiac imaging in accordance with the invention; by way of example, an initial administration of 150  $\mu\text{g/kg}$  of adenosine may be made substantially simultaneously with administration of the contrast agent, followed 10 seconds later by slow injection of a further 150  $\mu\text{g/kg}$  of adenosine, e.g. over a period of 20 seconds.

One category of accumulative contrast agents useful in accordance with the invention comprise gas-containing contrast agent preparations which promote controllable and temporary growth of the gas phase *in vivo* following administration owing to the presence of a diffusible component capable of inward diffusion into the dispersed gas phase to promote temporary growth thereof, thereby acting as deposited perfusion tracers. Such compositions therefore comprise:

- i) an injectable aqueous medium having gas dispersed therein; and
- ii) a composition comprising a diffusible component capable of diffusion *in vivo* into said dispersed gas so as at least transiently to increase the size thereof. Accumulative contrast agents of this type are extensively described in WO-A-9817324, the contents of which are incorporated herein by reference.

The dispersed gas in such a preparation may, for example, comprise air, nitrogen, oxygen, carbon dioxide, hydrogen, an inert gas, a sulphur fluoride, selenium hexafluoride, an optionally halogenated silane, an optionally halogenated low molecular weight hydrocarbon (e.g. having a molecular weight such that it is substantially or completely in gaseous form at the

- 6 -

normal human body temperature of 37°C), a ketone, an ester or a mixture of any of the foregoing. The use of perfluorinated gases, for example sulphur hexafluoride, perfluorinated ketones, perfluorinated ethers and  
5 perfluorocarbons, including perfluoroalkanes such as a perfluoropropane, perfluorobutane or perfluoropentane, perfluoroalkenes and perfluorocycloalkanes, may be particularly advantageous in view of the recognised high stability in the bloodstream of microbubbles containing  
10 such gases.

The dispersed gas may, for example, be in the form of microbubbles stabilised (e.g. at least partially encapsulated) by a coalescence-resistant surface membrane such as gelatin, a filmogenic protein (e.g. an  
15 albumin such as human serum albumin), a polymer material, a non-polymeric and non-polymerisable wall-forming material or a surfactant (e.g. a phospholipid, preferably such that at least 75% of the surfactant material comprises molecules individually bearing net  
20 overall charge, for example negative charge as in phosphatidylserines, phosphatidylglycerols, phosphatidylinositols, phosphatidic acids and cardiolipins).

The diffusible component may advantageously be  
25 dispersed in an aqueous carrier liquid in the form of an oil-in-water emulsion or microemulsion and may, for example, comprise an aliphatic ether such as diethyl ether; a polycyclic oil or alcohol such as menthol, camphor or eucalyptol; a heterocyclic compound such as  
30 furan or dioxane; an aliphatic hydrocarbon or cycloaliphatic hydrocarbon, e.g. containing up to 7 carbon atoms; or halogenated low molecular weight hydrocarbon, e.g. containing up to 7 carbon atoms. The use of perfluorocarbons, e.g. a perfluoroalkane such as  
35 perfluoropentane or perfluorohexane, a perfluoroalkene, a perfluorocycloalkane such as perfluorodimethylcyclobutane, or a perfluorinated alcohol may be advantageous.

Where the diffusible component is formulated as an

- 7 -

emulsion it may advantageously be stabilised using a phospholipid surfactant, e.g. as described above in connection with the stabilisation of gas dispersions.

5 The diffusible component may be administered by any appropriate route, for example cutaneously, subcutaneously, intramuscularly, intravenously or by inhalation.

10 A further class of accumulative ultrasound contrast agent which may be used in accordance with the invention comprises phase shift colloids such as are described in WO-A-9416739, the contents of which are incorporated herein by reference. Such agents comprise colloidal  
15 dispersions of the liquid-in-liquid type in which the dispersed liquid has a boiling point below the body temperature of the subject to be imaged, so that it may volatilise to form expanding gas microbubbles following administration. Representative examples of such agents include emulsions of volatile hydrocarbons, particularly perfluorocarbons such as perfluoropentane, for example  
20 stabilised with surfactants such as phospholipids, e.g. as described above in relation to emulsions of diffusible components.

A still further class of accumulative ultrasound contrast agents which may be used in accordance with the  
25 invention comprises targetable ultrasound contrast agents having affinity for sites and/or structures within tissue microvasculature. Such targetable agents will typically comprise (i) a reporter moiety capable of interacting with ultrasound irradiation to generate a  
30 detectable signal; (ii) one or more vectors having affinity for particular target sites and/or structures; and (iii) one or more linkers connecting said reporter and vector(s), in the event that these are not directly joined.

35 Reporters which may be useful in such targetable agents include any of the gas-containing systems hereinbefore described in the context of gas-containing

- 8 -

ultrasound contrast agent formulations.

The targetable agents may, for example, comprise vectors which have affinity for normal or activated endothelial cells such that they target the vascular  
5 endothelium and become at least transiently concentrated on the walls of blood vessels. Activation of endothelium may for example be caused by microbial infections, infarcts or ischemia. Representative vectors in this context include ligands for cell adhesion  
10 molecules, for instance proteins or carbohydrate-containing molecules, as well as cell adhesion molecules themselves where these have corresponding ligands on endothelial cell surfaces.

Examples of cell adhesion molecules occurring on  
15 activated endothelial cell surfaces include integrins, such as ICAM-1, most of which bind the Arg-Gly-Asp (RGD) amino acid sequence. Specific cell adhesion molecules may occur, or occur in elevated amounts, in relation to the formation of thrombi, for instance blood coagulation  
20 factors, e.g. such as Factor XIII, and glycoproteins such as GP IIb/IIIa on activated blood platelets. Thrombi may be targeted by platelet binding peptides such as PLYKKIIKKLLES, NDGDFEEIPEEYLQ and GPRG. Atherosclerotic plaques may be targeted by specific  
25 peptides such as YRALVDTLK, YAKFRETLEDTRDRMY and RALVDTEFKVKQEAGAK. Damaged vessel walls may expose targetable myocyte-specific molecules. Angiogenesis may cause elevation of receptors to VEGF and tumours may be targeted by cholecystokinin,  $\alpha$ -melanocyte-  
30 stimulating hormone, heat stable enterotoxin 1, vasoactive intestinal peptide,  $\alpha_v\beta_3$  (vitronectin receptor), uPAR (urokinase plasminogen activator receptor), oncofetal fibronectin, synthetic  $\alpha$ -M2 peptide from the third heavy chain complementarity-  
35 determining region and analogues thereof. Further references to this technology, e.g. in targeting to fibrin, thrombi and atherosclerotic areas are found in

publications by Alkanonyuksel, H et al. in J. Pharm. Sci. (1966) 85 (5), 486-490; J. Am. Coll. Cardiol. (1996) 27 (2) Supl A, 298A; and Circulation, 68 Sci. Sessions; Anaheim, 13-16 November 1995.

5           Other vectors which may be used include proteins and peptides which bind to cell-surface proteoglycans. Such proteoglycans, which are complexes of proteins and sulphated polysaccharides, are found on most cells, including endothelial cells, and contribute to the  
10       negative surface charge exhibited by all eukaryotic cells. This charge may be exploited in accordance with this embodiment of the invention by using vectors which will interact electrostatically with the endothelial surface, for example vectors comprising cationic lipids.

15           Linking of a reporter unit to a desired vector or vectors may be achieved by covalent or non-covalent means, usually involving interaction with one or more functional groups located on the reporter and/or the vector(s). Examples of chemically reactive functional  
20       groups which may be employed for this purpose include amino, hydroxyl, sulfhydryl, carboxyl and carbonyl groups, as well as carbohydrate groups, vicinal diols, thioethers, 2-aminoalcohols, 2-aminothiols, guanidinyll, imidazolyl and phenolic groups. Covalent coupling of  
25       reporter and vector(s) may therefore be effected using linking agents containing reactive moieties capable of reaction with such functional groups, e.g. as is well known in the art.

          Various vectors and linking agents which it may be  
30       useful to adopt in targetable ultrasound contrast agents in accordance with this embodiment of the invention are disclosed in EP-A-0727225 and WO-A-9640285. Suitable vectors, linkers etc. may also be selected from the wide range of known vectors and linking groups summarised in  
35       WO-A-9818495, WO-A-9818498, WO-A-9818500 and WO-A-9818501. The contents of all these documents are incorporated herein by reference.

- 10 -

Representative ultrasound imaging techniques which may be useful in accordance with the invention include fundamental B-mode imaging; harmonic B-mode imaging including reception of sub-harmonics and the second and higher harmonics; tissue Doppler imaging, optionally including selective reception of fundamental, harmonic or sub-harmonic echo frequencies; colour Doppler imaging, optionally including selective reception of fundamental, harmonic or sub-harmonic echo frequencies; power Doppler imaging, optionally including selective reception of fundamental, harmonic or sub-harmonic echo frequencies; power or colour Doppler imaging utilising loss of correlation or apparent Doppler shifts caused by changes in the acoustical properties of contrast agent microbubbles such as may be caused by spontaneous or ultrasound-induced destruction, fragmentation, growth or coalescence; pulse inversion imaging, optionally including selective reception of fundamental, harmonic or sub-harmonic echo frequencies, and also including techniques wherein the number of pulses emitted in each direction exceeds two; pulse inversion imaging utilising loss of correlation caused by changes in the acoustical properties of contrast agent microbubbles such as may be caused by spontaneous or ultrasound-induced destruction, fragmentation, growth or coalescence; pulse pre-distortion imaging, e.g. as described in 1997 IEEE Ultrasonics Symposium, pp. 1567-1570; and ultrasound imaging techniques based on comparison of echoes obtained with different emission output amplitudes or waveform shapes in order to detect non-linear effects caused by the presence of gas bubbles.

The following non-limitative examples serve to illustrate the invention.

- 11 -

Preparation 1a) Perfluorobutane gas dispersion

5 Hydrogenated phosphatidylserine (100 mg) in a 2%  
solution of propylene glycol in purified water (20 ml)  
was heated to 80°C for 5 minutes and the resulting  
dispersion was allowed to cool to room temperature  
overnight. 1 ml portions were transferred to 2 ml  
10 vials, the headspace above each portion was flushed with  
perfluorobutane gas, and the vials were shaken for 45  
seconds using an Espe CapMix® mixer for dental  
materials, yielding milky white microbubble dispersions  
with a volume median diameter of 5.0  $\mu\text{m}$ , measured using  
15 a Coulter Counter (all Coulter Counter measurements were  
made at room temperature using an instrument fitted with  
a 50  $\mu\text{m}$  aperture and having a measuring range 1-30  $\mu\text{m}$ ;  
Isoton II was used as electrolyte).

20 b) Dispersion of lyophilised perfluorobutane gas  
dispersion

A sample of the milky white dispersion prepared as in  
(a) above was washed three times by centrifugation and  
25 removal of the infranatant, whereafter an equal volume  
of 10% sucrose solution was added. The resulting  
dispersion was lyophilised and then redispersed in  
distilled water just prior to use.

30 Preparation 2

Perfluoromethylcyclobutane emulsion

Hydrogenated phosphatidylserine (100 mg) in purified  
35 water (20 ml) was heated to 80°C for 5 minutes and the  
resulting dispersion was cooled to 0°C overnight. 1 ml  
of the dispersion was transferred to a 2 ml vial, to

- 12 -

which was added 100  $\mu$ l of perfluorodimethylcyclobutane (>97% 1,1-isomer, balance being 1,2- and 1,3-isomers). The vial was then shaken for 75 seconds using a CapMix® to yield an emulsion of diffusible component which was stored at 0°C when not in use.

Example 1 - In vivo imaging of dog heart with perfluorobutane gas dispersion and perfluorodimethylcyclobutane emulsion and coadministered adenosine

10

An occluding snare was placed around a major branch of the left anterior descending coronary artery of an open-chest 22 kg dog and an ultrasound transit time flowmeter was placed immediately downstream of the occluder, which was then adjusted to produce a steady 25% flow reduction from about 14 to 10 ml/min. The contents of three syringes, respectively containing (i) an amount of a perfluorobutane microbubble dispersion prepared as in Preparation 1 corresponding to 4.4  $\mu$ l of gas content, (ii) an amount of the perfluorodimethylcyclobutane emulsion from Preparation 2 corresponding to 33  $\mu$ l of the dispersed perfluorodimethylcyclobutane phase, and (iii) 3.0 mg adenosine dissolved in 0.9% saline, were then intravenously injected as a simultaneous bolus; commencing 10 seconds later a further 3.0 mg of adenosine dissolved in 0.9% saline was injected slowly over 20 seconds. Imaging of the left ventricle of the heart was performed using an ATL HDI-3000 scanner with a P5-3 probe; continuous ultrasonication at maximum power was applied for 1 minute to induce microbubble growth, whereafter the myocardium was examined using B-mode imaging. A clearly evident difference in gray scale levels could be seen between stenotic areas (brighter than baseline recordings) and normal areas (very much brighter than baseline recordings).

- 13 -

Example 2 - [Comparative]

The procedure of Example 1 was repeated, but without injection of adenosine. The differences in contrast intensity between areas supplied by normal and stenotic arteries were now only barely visible; the main difference from Example 1 was that the brightness of normal areas was reduced to a level closer to that of the regions supplied by the stenotic artery.

10

Example 3 - Imaging with contrast agent under dobutamine stress

Example 1 was repeated except that a continuous infusion of dobutamine at a rate of 15  $\mu\text{g/kg/min}$  was administered in place of adenosine. After a stable dobutamine effect consisting of an increase in heart rate from the normal 100 beats per minute to 150 beats per minute was obtained, the microbubble dispersion and the emulsion were intravenously injected from two syringes as a simultaneous bolus. Infusion of dobutamine was continued for another 2 minutes after the contrast agent injection. Towards the end of this period, a distinct pattern of myocardial contrast enhancement was seen, clearly depicting the areas supplied from the stenotic artery as darker than the normal myocardium. In addition, a myocardial contractility deficit consisting of a pronounced wall thinning was observed in the areas supplied by the stenotic artery.

30

- 14 -

Claims

1. A combined preparation for use as a contrast agent in ultrasound perfusion imaging, said preparation  
5 comprising:  
    i) an ultrasound contrast agent capable of accumulation in tissue microvasculature; and  
    ii) a pharmacologically effective amount of a vasodilator drug.
- 10 2. A preparation as claimed in claim 1 wherein said vasodilator drug is an endogenous substance.
- 15 3. A preparation as claimed in claim 2 wherein said vasodilator drug is adenosine.
4. A preparation as claimed in any one of claims 1 to 3 wherein said ultrasound contrast agent comprises:  
    i) an injectable aqueous medium having gas  
20 dispersed therein; and  
    ii) a composition comprising a diffusible component capable of diffusion in vivo into said dispersed gas so as at least transiently to increase the size thereof.
- 25 5. A preparation as claimed in any one of claims 1 to 3 wherein said ultrasound contrast agent comprises a phase shift colloid.
- 30 6. A preparation as claimed in any one of claims 1 to 3 wherein said ultrasound contrast agent comprises a targetable ultrasound contrast agent having affinity for sites and/or structures within tissue microvasculature.
- 35 7. A preparation as claimed in claim 6 wherein said ultrasound contrast agent comprises at least one vector having affinity for normal or activated endothelial

- 15 -

cells.

8. A preparation as claimed in claim 6 wherein said  
ultrasound contrast agent comprises at least one protein  
5 or peptide which binds to cell-surface proteoglycans.

9. A method of generating enhanced perfusion images of  
a human or non-human animal subject which comprises the  
steps of:

10 i) injecting an ultrasound contrast agent capable  
of accumulation in tissue microvasculature into the  
vascular system of said subject;

ii) coadministering a pharmacologically effect  
amount of a vasodilator drug; and

15 iii) generating an ultrasound image representing  
perfusion of a target organ or tissue.

10. A method as claimed in claim 9 wherein images  
representative of myocardial perfusion are generated.

20

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB 98/03155

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K49/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 98 17324 A (MARSDEN JOHN CHRISTOPHER ; ERIKSEN MORTEN (NO); OESTENSEN JONNY (NO) 30 April 1998 see page 30, line 23-38; claims 22,23,28,29; examples 1A,2,24,32 see page 31, line 28-30 ---	1-10
X,P	WO 98 10799 A (IMARX PHARMACEUTICAL CORP) 19 March 1998 see page 71, line 18-21; claims 33-35; example 2	1-10
Y	see page 71, line 28-32 ---	1-10
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

29 January 1999

Date of mailing of the international search report

16/02/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Gonzalez Ramon, N

International Application No.  
PCT/GB 98/03155

6

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/03155

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ILICETO S. ET AL: "Myocardial contrast echocardiography in acute myocardial infarction. Pathophysiological background and clinical applications" EUROPEAN HEART JOURNAL, vol. 17, 1996, pages 344-353, XP002091306 see abstract see page 350, column 2 - page 351 ---	1-5,9,10
X	FIRSCHKE C. ET AL: "Myocardial contrast echocardiography in acute myocardial infarction using aortic root injections of microbubbles in conjunction with harmonic imaging: potential application in the cardiac catheterization laboratory" J. AM. COLL. CARDIOL., vol. 29, no. 1, January 1997, pages 207-216, XP002091413 see abstract see page 215 -----	1-5,9,10

# INTERNATIONAL SEARCH REPORT

I. International application No.

PCT/GB 98/03155

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim(s) 9, 10  
is(are) directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/03155

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9817324 A	30-04-1998	AU 4714797 A	15-05-1998
WO 9810799 A	19-03-1998	AU 4089897 A	02-04-1998
		AU 4235697 A	02-04-1998
		WO 9810798 A	19-03-1998
		US 5846517 A	08-12-1998
WO 9640285 A	19-12-1996	AU 6270396 A	30-12-1996
		CA 2218541 A	19-12-1996
		EP 0831932 A	01-04-1998
WO 9818498 A	07-05-1998	AU 4786897 A	22-05-1998
		AU 4786997 A	22-05-1998
		AU 4787097 A	22-05-1998
		WO 9818496 A	07-05-1998
		WO 9818497 A	07-05-1998
		AU 4786697 A	22-05-1998
		AU 4786797 A	22-05-1998
		WO 9818501 A	07-05-1998
		WO 9818495 A	07-05-1998
		AU 4718297 A	22-05-1998
		WO 9818500 A	07-05-1998
		WO 9847541 A	29-10-1998
WO 9818501 A	07-05-1998	AU 4786697 A	22-05-1998
		AU 4786897 A	22-05-1998
		AU 4786997 A	22-05-1998
		WO 9818496 A	07-05-1998
		WO 9818497 A	07-05-1998
		AU 4786797 A	22-05-1998
		AU 4787097 A	22-05-1998
		WO 9818495 A	07-05-1998
		WO 9818498 A	07-05-1998
		AU 4718297 A	22-05-1998
		WO 9818500 A	07-05-1998
		WO 9847541 A	29-10-1998